60 Degrees Pharmaceuticals (SXTP) News Today $1.30 +0.00 (+0.31%) As of 09:41 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock SXTP Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period 60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment ConferenceAugust 21, 2025 | globenewswire.com60 Degrees selects Icahn School of Medicine as central site for Phase II studyAugust 19, 2025 | msn.com60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisAugust 19, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces Second Quarter 2025 ResultsAugust 13, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public OfferingJuly 16, 2025 | globenewswire.com60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration ...July 15, 2025 | finanznachrichten.de60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public OfferingJuly 15, 2025 | globenewswire.com60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 BillionJuly 15, 2025 | globenewswire.comSXTP - 60 Degrees Pharmaceuticals Inc Valuation - MorningstarJuly 3, 2025 | morningstar.comM60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Director Cheryl Xu Acquires 5,000 SharesJune 6, 2025 | insidertrades.com60 Degrees Pharmaceuticals Reports Significant Discrepancy in Babesiosis Case Estimates and Plans for New Drug Application in 2026June 5, 2025 | nasdaq.com60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle FormatJune 4, 2025 | globenewswire.comBabesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees PharmaceuticalsJune 3, 2025 | globenewswire.com60 Degrees Pharmaceuticals Announces First Quarter 2025 ResultsMay 15, 2025 | globenewswire.comBabesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma SurveyApril 22, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comGeoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21April 10, 2025 | globenewswire.comSixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public HealthApril 8, 2025 | globenewswire.com60 Degrees Pharmaceuticals, Inc.April 4, 2025 | uk.investing.com60 Degrees Pharmaceuticals announces 1-for-5 reverse stock splitFebruary 20, 2025 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock SplitFebruary 20, 2025 | globenewswire.com60 Degrees says FDA does not object to tafenoquine import planFebruary 11, 2025 | markets.businessinsider.comSixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®February 11, 2025 | globenewswire.comInsiders Give Up US$71k As 60 Degrees Pharmaceuticals Stock Drops To US$0.55February 9, 2025 | finance.yahoo.com60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 6, 2025 | globenewswire.com60 Degrees prices 1.5M shares at 71.5c in registered direct offeringFebruary 5, 2025 | markets.businessinsider.com60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesFebruary 5, 2025 | globenewswire.com60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 30, 2025 | globenewswire.com60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesJanuary 29, 2025 | markets.businessinsider.com60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic BabesiosisJanuary 28, 2025 | globenewswire.com60 Degrees Pharmaceuticals enrolls first patient in tafenoquine studyJanuary 9, 2025 | finance.yahoo.com60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) BabesiosisJanuary 8, 2025 | globenewswire.com60 Degrees signs patent license deal with Tufts Medical, says H.C. WainwrightDecember 25, 2024 | markets.businessinsider.com60 Degrees, Tufts Medical Center announces patent license agreementDecember 24, 2024 | finance.yahoo.comSixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and PreventionDecember 23, 2024 | globenewswire.com60 Degrees expands tafenoquine clinical trial to Brigham and Women’s HospitalDecember 12, 2024 | markets.businessinsider.comH.C. Wainwright Sticks to Its Hold Rating for 60 Degrees Pharmaceuticals, Inc. (SXTP)December 12, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s HospitalDecember 11, 2024 | finance.yahoo.com60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women's HospitalDecember 11, 2024 | globenewswire.comInsider Buying: 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) CEO Buys 17,549 Shares of StockDecember 10, 2024 | insidertrades.com60 degrees pharmaceuticals CEO Geoffrey Dow acquires $6,367 in stockNovember 23, 2024 | investing.com60 Degrees Pharmaceuticals Announces Third Quarter 2024 ResultsNovember 14, 2024 | globenewswire.com60 Degrees (NASDAQ:SXTP) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.com60 Degrees (NASDAQ:SXTP) Stock, Short Interest ReportOctober 4, 2024 | benzinga.com60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. LaunchOctober 3, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 7, 2024 | markets.businessinsider.com60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq RulesSeptember 4, 2024 | globenewswire.com60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing RequirementsAugust 28, 2024 | globenewswire.com60 Degrees Pharmaceuticals Second Quarter 2024 Earnings: Misses ExpectationsAugust 18, 2024 | finance.yahoo.com Get 60 Degrees Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SXTP and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SXTP Media Mentions By Week SXTP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SXTP News Sentiment▼0.941.03▲Average Medical News Sentiment SXTP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SXTP Articles This Week▼11▲SXTP Articles Average Week Get the Latest News and Ratings for SXTP and Related Stocks Enter your email address to receive the latest news and analysts' ratings for 60 Degrees Pharmaceuticals and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies AYTU News Today ABP News Today AIMD News Today ATNF News Today LEXX News Today EDSA News Today LSB News Today CYCC News Today LPCN News Today MBRX News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SXTP) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 60 Degrees Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 60 Degrees Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access